Teva Pharm Stock Price, News & Analysis

Teva Pharmaceuticals has launched the Honestly HD website to assist the Huntington's Disease (HD) community in understanding chorea symptoms and communicating with healthcare providers. The site offers resources for managing HD chorea, which affects 90% of those with HD, potentially impacting daily life. Alongside the website, a Twitter channel and Facebook community have been introduced to foster support. Teva emphasizes its commitment to helping patients navigate the challenges posed by this degenerative disease.

Teva Pharmaceutical Industries has presented two studies at the Migraine Trust International Symposium (MTIS) in London, showcasing the efficacy of AJOVY (fremanezumab) for treating migraine in patients with co-morbid depression and anxiety. Results showed over 50% reduction in monthly migraine attacks in patients taking AJOVY compared to placebo. The studies highlight the importance of addressing psychiatric comorbidities in migraine treatment. Teva aims to provide personalized treatment options, with ongoing research including the UNITE study assessing AJOVY's effectiveness in managing chronic migraine with major depressive disorder.

Teva Pharmaceuticals announced promising results from the CONNECT1 study, comparing the ProAir Digihaler to standard albuterol inhalers for asthma management. Patients using the Digihaler saw an 85.3% increase in improving asthma control after three months. The study, involving 333 participants, highlighted that those with the Digihaler had better adherence discussions with physicians and experienced fewer SABA inhalations. Additionally, 61% of Digihaler users achieved well-controlled asthma compared to 55% in the standard care group. The findings underscore the potential of digital tools in asthma management.

Pyramid Biosciences has expanded its leadership team by appointing Biren Amin as Chief Financial and Strategy Officer. Amin, previously CFO at Immuneering Corporation (NASDAQ: IMRX), brings over two decades of experience in oncology and biotechnology. The company is focused on developing precision therapies for cancer, particularly with its lead program PBI-200, a TRK inhibitor for NTRK fusion-driven cancers. The CEO expressed confidence in Amin's expertise to guide corporate strategy and advance the product pipeline during a period of significant growth for the company.

Teva Pharmaceutical Industries announced findings from the CONNECT clinical program regarding the ProAir Digihaler System, designed to enhance asthma control. The CONNECT1 trial assessed 333 asthma patients over 12 weeks and compared the Digihaler's effects on asthma management against standard care. Initial results will be presented at the European Respiratory Society Congress on September 6, 2022, focusing on asthma control improvements and enhancing patient-physician interactions. The ProAir Digihaler incorporates an electronic module to track inhaler use and support informed treatment decisions.

Teva Pharmaceuticals has received Marketing Authorization from the European Commission for Ranivisio (ranibizumab), a biosimilar to Lucentis, targeting age-related macular degeneration (AMD) and four other ophthalmology indications. AMD currently affects approximately 67 million individuals in Europe and is predicted to impact up to 77 million by 2050. Teva aims to commercialize this product across Europe through a partnership with Bioeq AG, following its UK launch in July 2022 under the name ONGAVIA®.

Teva Pharmaceutical Industries Ltd. has agreed in principle on the primary financial terms of a nationwide opioids settlement, revising its provision to reflect this. The company reported Q2 2022 revenues of $3.8 billion, with a GAAP diluted loss per share of $0.21 and a non-GAAP diluted EPS of $0.68. The 2022 revenue outlook has been revised down to $15.0 - $15.6 billion, mainly due to foreign exchange headwinds and increased competition for COPAXONE®, which is now expected to generate around $700 million. The company aims to finalize the settlement documentation soon.

Teva Pharmaceuticals has reached a settlement with the City and County of San Francisco regarding opioid-related claims, providing $24.8 million over 13 years and $20 million worth of generic Narcan over 10 years. This settlement, while not an admission of liability, aims to deliver life-saving treatments for opioid addiction. Previously, a California Superior Court judge found that Teva did not cause a public nuisance related to opioids in several counties. Teva continues to pursue a nationwide settlement in the interest of those benefiting from its medicines.

Teva Pharmaceutical Industries Ltd. announced the appointment of Eric A. Hughes as Executive Vice President, Global R&D and Chief Medical Officer, effective August 1, 2022. Dr. Hughes brings nearly 20 years of experience in drug development, previously serving at Vertex Pharmaceuticals and Novartis. His expertise in leading clinical development and collaborations is expected to enhance Teva's Global R&D initiatives. CEO Kåre Schultz expressed gratitude to former executive Dr. Hafrun Fridriksdottir for her 25 years of service while highlighting the potential growth opportunities with Dr. Hughes's leadership.